CEO Alice Zhang Speaks at 2017 Partnering For Cures Conference
Alice Zhang speaks about Verge Genomics' A.I.-enabled approaches to drug discovery
November 14, 2017
SAN FRANCISCO — Verge Genomics CEO Alice Zhang was invited to speak on a plenary panel session featuring industry leaders in A.I.-enabled drug discovery at the annual Partnering for Cures conference hosted by Faster Cures, a Center of the Milken Institute. At the panel, titled "Artificial Intelligence and Machine Learning in Medical R&D: Hope or Hype?", Zhang discussed Verge's unique approach combining machine learning genomic network analysis with neurobiology to tackle neurodegenerative diseases and the promise that these approaches hold to reduce drug discovery times and enable precision medicine.
Since 2009, Partnering for Cures has been convening leaders with the experience, creativity, and motivation needed to transform the medical research system. It is convened annually by FasterCures, a center of the Milken Institute, and connects decision-makers from across diseases who are motivated by the same mission – to reduce the time and cost of getting new therapies from discovery to patients.
About Verge Genomics
Verge is a next-generation drug discovery company that is using human genomic data to accelerate the discovery of treatments for neurodegeneration. Founded by scientists from leading neuro-genomics labs, the Verge team is 14 people including 12 Ph.D.’s in machine learning, neuroscience, applied math, biophysics, statistics, and computational biology from UCLA, Stanford, Oxford, and UCSF, two former professors, and two pharma veterans.